

Asst. Prof. Mongkol Chanvanichtrakool Division of Neurology, Department of Pediatrics Faculty of Medicine Siriraj Hospital

#### Outline


- Introduction to genomic era
- Type of genetic testing
- Pre-genetic testing counseling
- Case-based discussion
- How to handle the genetic result



#### Innovations in Genetic testing


Over 1,000 genes
have been identified
that have been
associated with
monogenic epilepsy

Next-Generation Sequencing (NGS)





# Treemap of Tier 1 epilepsy genes characterized in Gene Ontology term (GO) groups





#### Why is genetic testing important?



End of Diagnostic odyssey



Connecting with with a support group



Reduce unnecessary investigation



Personalized treatment




Screening for comorbidities



Opportunity for future research



# Epilepsy-related genetic conditions displaying potential specific therapeutic approaches



## How to choose genetic testing

#### Outline

- Introduction to genomic era
- Type of genetic testing
- Pre-genetic testing counseling
- Case-based discussion
- How to handle the genetic result

# Matching Genetic Disorder with Appropriate Testing

Monogenic disorder

Chromosomal disorder

**CNV** disorder

Imprinting disorder

Repeat expansion disorder

Mosaicism



Chromosome study

FISH

Methylation test

Chromosome microarray (SNP/CGH)

Gene panel

Whole exome sequencing

Whole genome sequencing(long read/short read)

## Type of Genetic Testing

Cytogenetic	Biochemical	Molecular
<ul><li>Karyotype</li><li>FISH</li><li>CMA</li></ul>	<ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Comprehensive metabolic test</li> <li>Enzyme assays</li> </ul>	<ul> <li>Sanger sequencing</li> <li>MLPA</li> <li>NGS</li> <li>Gene panel</li> <li>ES</li> <li>GS</li> </ul>

CMA: Chromosome microarray


ES: Exome sequencing GS: Genome sequencing

MLPA: Multiplex Ligation-Dependent Probe Amplification

NGS: Next generation sequencing

### Conventional karyotyping


- Detect
  - Chromosomal abnormalities of 5
     Mb and larger
  - 2–3 Mb (high-resolution banding)
- Analyze chromosomes for chromosomal rearrangements
  - Balanced or unbalanced translocations
  - Inversions
  - Ring chromosome




Ring chromosome 15

#### FISH

- Specific probe
- Resolution: 150-200 kb
- Can not detect uniparental disomy




### Next generation sequencing










#### Resolution

	Resolution	Applications	Limitations
Karyotyping	2-3 Mb / 5 Mb	Scanning for aneuploidy, large deletion or duplication and structural variants	Cannot identify microdeletion/duplication
CMA: SNP array	Few kb or longer	Scanning the entire genome for any CNV, Can identify ROH	Cannot identify balanced translocation and inversion
CMA: Array-CGH	Few kb or longer	Scanning the entire genome for any CNV	Same as SNP-array. Cannot identify ROH
Gene panel	One to several bp	Scanning for genes of interest. Can be supplemented with other technologies to solve low-coverage regions and detect small CNV.  "True" panel testing with deep coverage can detect low-level mosaicism.	Cannot detect deep-intronic changes. Different labs have different set of genes for targeted phenotype.
ES	One to several bp	Scanning for all genes of interest excluding non-coding and deep intronic regions.	Might miss variants in low- coverage regions and deep intronic changes, low-level mosaicism. Less reliable for copy number calling.
GS	One to several bp	Scanning for entire genome including non-coding and deep intronic regions.	Costly and mostly research- driven. Most variants in non- coding regions are uninterpretable

### Diagnostic yield in genetic testing



#### Genetic Counseling

- Types of Genetic Testing Performed on Patients
- Sample Collection
- Advantages of Genetic Testing
  - Personalized treatment
  - Prognostic information and guidance
  - Recurrence risk assessment
- Possible Results
  - Positive findings
  - Negative findings
  - Variants of uncertain significance (VUS)
  - Secondary findings (ES/GS)

#### Outline

- Introduction to genomic era
- Type of genetic testing
- Pre-genetic testing counseling
- Case-based discussion
- How to handle the genetic result

## Approach

History taking & Physical examination

Initial investigation (eg. EEG, MRI brain)

Identify Diseases/Syndromes
Based on Clinical Clues

Tailored Genetic testing
Depend on Genetic disorders

## Wolf-Hirschhorn syndrome

- 4p Deletion
- Onset: 6 to 12 months of age
- Seizure type: GTC, tonic spasm, focal seizure
- Facial dysmorphism
- Triggered by fever
- Developmental delay
- Heart defect, Hearing defect
- Recommended ASMs: CLB, LEV
- ASMs to Avoid: PHT, CBZ, OXZ





 Four-year-old girl presented with developmental regression, hand wringing movement and progressive microcephaly

MECP2 sequencing: negative

Suspected disease

Rett syndrome

Molecular pathology

Monogenic disorder

Genetic testing

Single testing vs gene panel



### What causes a negative result?

#### 1. Limitations of single-gene sequencing:

Unable to detect copy number variation (CNV) disorders

#### Genetic abnormalities in MECP2

Gene	Method	Proportion of Pathogenic Variants
MECP2	Sequence analysis	90%-95%
	Gene-targeted deletion/duplication analysis	5%-10%

https://www.ncbi.nlm.nih.gov/books/NBK1497/

MECP2, Deletion (Exon 4), heterozygous (gene panel)



## What causes a negative result?

- 2. Alternative diagnosis (Rett-like syndrome)
  - Angelman syndrome
  - Other genetic disorders

such as FOXG1, CDKL5, GABBR2, PPT1



#### Case 3

- 12-year-old boy
- Presented with GT seizure at 4 months related with fever.
- He had recurrent/prolong febrile seizure.
- Other seizure type: focal seizure, myoclonic seizure
- U/D: Developmental delay
- MRI brain: normal
- Drug resistance




#### Dravet syndrome


- Loss of function in SCN1A gene (65-80% of patients)
- Onset: 4-7 months (mean 5 months)
- Seizure
  - Febrile seizures, prolong or cluster
  - Multiple type seizures (GT, hemiclonic Sz, myoclonic seizure)
- Triggering Factors: Fever, Hot bath, Vaccine, Sodium channel blocker
- Developmental delay
- Drug resistance



## Crouch gait



## Approach






#### Case 4

#### After pyridoxine treatment

- 3-month-old girl
- Presented with refractory status epilepticus 2 day ago
- Failed ASM: PHB, LEV, MDZ, Pentobarbital
- U/D: Developmental delay
- CT brain: Mild hydrocephalus



Suspected disease

Molecular pathology

Genetic testing

Pyridoxine dependent epilepsy

ALDH7A1 gene

Gene panel



### Who should get genetic testing?

- Unexplained refractory epilepsies
- Neonatal with epileptic encephalopathies (up to 83%)
- Children with onset < 3 years (37%)</li>
- Epilepsy with developmental delay or regression
- Suspicious genetic epileptic syndrome
  - EIEE, Dravet syndrome, familial self-limited epileptic syndrome, DEE
- Features suggest a genetic syndrome eg. dysmorphic facies

#### Outline

- Introduction to genomic era
- Type of genetic testing
- Pre-genetic testing counseling
- Case-based discussion
- How to handle the genetic result





#### Managing Genetic Test Results

Negative

Positive

VUS









#### How to Handle a Positive Result



**RESULT: POSITIVE** 

One Pathogenic variant identified in SCN1A. SCN1A is associated with a spectrum of autosomal dominant seizure and other neurological and musculoskeletal conditions.


Additional Variant(s) of Uncertain Significance identified.

GENE	VARIANT	ZYGOSITY	VARIANT CLASSIFICATION
SCN1A	c.680T>G (p.lle227Ser)	heterozygous	PATHOGENIC


SCN1A



Dravet syndrome









#### How to Handle a Positive Result

No need to memorize diseases; just know how to find the information







NIH National Library of Medicine National Center for Biotechnology Information			
ClinVar	ClinVar	Search ClinVar by gene	




#### How to Handle a Positive Result



#### Personalized medicine

- Dravet syndrome:
  - avoid Na channel blocker,
     Antisense oligonucleotide
- SCN8A or SCN2A related DEE (GOF):
  - Sodium channel blocker, Relutrigine (PRAX-562)



#### Surveillance

- Rett syndrome
  - QT prolong (18-55%)



## Genetic counseling and family planning

- Prenatal diagnosis
- Preimplantation diagnosis
- Carrier testing
- Advice prognosis



#### How to Handle a Negative Result

- Review test limitations
- Consider alternative diagnoses
- Reevaluate the patient's condition
  - Some phenotypes may emerge with age
  - Ongoing discovery of new genes and conditions
  - Updates in genetic variant data



### Acknowledgement



















Siriraj Genomics







Division of Neurology Department of Pediatrics